Multiple sclerosis (MS) is an autoimmune disorder of multifactorial etiology. Family studies have shown strong genetic contributions. Linkage analyses have revealed several regions harboring risk genes including chromosome region 19q13. ILT6 is one of the most interesting candidate genes, since ILTs are involved in the generation of immunological tolerance. There is an absence/presence of variability of the ILT6 gene comprising several exons, thus incapacitating the gene function. In the present study, we examined the association of ILT6 deletion with MS. Using PCR typing, deficiency of ILT6 was examined in 607 blood donors and in 751 Caucasian German, as well as 89 French MS patients. Homozygous ILT6 deficiencies were significantly more prevalent in MS patients (7.1%) than in blood donors (3.8%; P ¼ 0.009). ILT6 deficiency is associated with MS in the German population and hence a likely risk factor for autoimmune disorders.
Multiple sclerosis (MS) is a common demyelinating disease affecting the central nervous system (CNS).
Family and twin studies have revealed a genetic contribution to the etiology of MS. [1] [2] [3] In partial genome screens several chromosomal regions including 6p21.3 (harboring the HLA locus) and 19q13 have been shown to carry risk genes. [4] [5] [6] On chromosome 19q13.4, the leukocyte receptor complex (LRC) is an internally homologous region that encodes at least 24 members of the immunoglobulin (Ig) superfamily. 7 The Ig-like transcript (ILT) or leukocyte Ig-like receptor (LILR) cluster contains at least 13 genes. 8 ILTs are expressed by monocytes, dendritic cells and lymphocytes and at least ILT2 9,10 and ILT4 10 bind to MHC class I molecules. ILTs regulate the immune response through inhibition or activation of cytolytic activity. 11 In addition, expression of ILT3 and ILT4 seems to be important in the generation of tolerance of T cells. 12 Polymorphisms of ILTs appear to be rather limited. However, the ILT6 gene exhibits a presence/absence variability, where individuals lack a 6.7-kbp segment comprising the first seven exons of the gene. 13 ILT6 is a secreted receptor with so far unknown binding specificity. It is homologous to ILT2, that binds to MHC class I molecules.
In order to study the association of ILT6 deficiency with MS, the presence or absence of exons 4-7 of the ILT6 gene was detected by PCR using primers flanking the deletion (Figure 1 ). Homozygous ILT6 deficiency was present in 53/751 (7.1%) German MS patients, but only in 23/406 (3.8%) German blood donors (p ¼ 0.009; Table 1 ). In addition, ILT6 was analyzed in 89 French MS patients and the prevalence of homozygous ILT6 deficiency was 9.0%. Since a control group of French blood donors was not available, no further statistical analysis was performed.
We then analyzed clinical subgroups of German MS patients, which had been recorded for 451 patients with a Figure 1 Example of ILT6 PCR in donor A (lanes 1 and 2), B (lanes 3 and 4) and C (lanes 5 and 6). In lanes 1, 3 and 5 the PCR samples of the reactions providing a 1150 bp product in case the wt ILT6 is present, and in lanes 2, 4 and 6 the PCR samples providing a 250 bp product in case the deletion is present were loaded. Donor A is homozygous for wtILT6, donor B is heterozygous and donor C homozygous for ILT6 deletion.
remitting relapsing (RRMS), 129 patients with a primary progressive course (PPMS) and 154 patients with a secondary progressive (SPMS) course. There was a significant association of RRMS with homozygous ILT6 deficiency, but not of PPMS and SPMS (Table 1) . In controls, the distribution of homo-and heterozygous ILT6 deletion did not differ from Hardy-Weinberg equilibrium.
The association of homozygous ILT6 deficiency with MS in the German population is the first disease association of a polymorphism of the ILT family. ILT appear to be involved in the induction of tolerance. Thus CD4 þ CD28
À alloantigen-specific T suppressor cells induce the upregulation of ILT3 and ILT4 on monocytes and dendritic cells, rendering these antigen-presenting cells (APCs) tolerogenic to CD4 þ T helper cells. 12 Paired Ig-like receptors (PIR) are the orthologs of the ILT in rodents since they map in the same location and share a similar sequence and gene structure. 14 Recently, PIR-B knockout mice have been shown to have a clearly increased B-cell activation and production of antibodies along with loss of tolerance. 15 The ILT6 gene does not harbor a transcribed transmembrane domain and, therefore, it is probably secreted. ILT6 is produced by monocytes. It has been suggested that ILT6 may be acting as an agonist for a related ILT binding to the same ligand. 16 Alternatively, it could be acting as a soluble mediator.
Although ILT6 deficiency was associated with MS, its prevalence in MS was low (7.1%). Many autoimmune disorders are polygenic and ILT6 deficiency may be one of many factors contributing to disease susceptibility. Clearly, ILT6 deficiency alone is not a prerequisite in development of MS. Recently, ILT6 alleles have been defined. 17 Some of these alleles are characterized by amino-acid exchanges in the putative ligand-binding domain. It will be interesting to examine whether these alleles in addition to ILT6 deficiency are associated with MS.
ILT6 deficiency was associated only with RRMS, but not with PPMS and SPMS. The differences between RRMS (8.0%), PPMS (7.0%) and SPMS (5.8%) are not significant however, and the lack of significant association of PPMS and SPMS with ILT6 deficiency may be due to the smaller sample size. Therefore, it cannot be concluded yet that ILT6 deficiency predisposes to a subgroup of MS.
Although ILT6 itself is a good candidate gene for MS, the observed association may be caused by its linkage disequilibrium with other genes. So far, at least in studies on SLE patients, we have not observed linkage of ILT6 deficiency with the repertoire of killer-Ig like receptors (KIR) which are adjacent to the ILT locus (unpublished observations). Therefore, the function of ILT6 has now to be studied in detail, since the gene may provide an important therapeutic tool for tolerance induction in general and MS in particular. OR ¼ odds ratio, 95% CI ¼ 95% confidence interval. P-value is indicated for homozygous ILT6 deletion. PCR on genomic DNA was performed using primers CCCCCTGGAGCTCGTGG and GACAGCAGATTCTAAAACAGTG to amplify the complete ILT6 (1150 bp amplicon length) and primers CATCTCGATCTGCCACTGACAC and GACAGCAGATTCTAAAACAGTG to amplify a fragment of 250 bp, when the ILT6 deletion is present. Case-control analysis between the MS and blood donor groups was performed using Fisher's exact test.
